Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 932371, 13 pages
http://dx.doi.org/10.1155/2010/932371
Review Article

Ovarian Cancer Pathogenesis: A Model in Evolution

1Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
2Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA

Received 1 June 2009; Accepted 23 June 2009

Academic Editor: Tian-Li Wang

Copyright © 2010 Alison M. Karst and Ronny Drapkin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA: A Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at Google Scholar
  2. P. Boyle and B. Levin, International Agency for Research on Cancer, and World Health Organization, “World cancer report 2008”, Distributed by WHO Press, Geneva, Switzerland, 2008.
  3. J. L. Benedet, H. Bender, H. Jones III, H. Y. Ngan, and S. Pecorelli, “FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology,” International Journal of Gynecology & Obstetrics, vol. 70, no. 2, pp. 209–262, 2000. View at Google Scholar
  4. L. H. Smith, C. R. Morris, S. Yasmeen, A. Parikh-Patel, R. D. Cress, and P. S. Romano, “Ovarian cancer: can we make the clinical diagnosis earlier?” Cancer, vol. 104, no. 7, pp. 1398–1407, 2005. View at Publisher · View at Google Scholar
  5. B. A. Goff, L. Mandel, H. G. Muntz, and C. H. Melancon, “Ovarian carcinoma diagnosis: results of a national ovarian cancer survey,” Cancer, vol. 89, no. 10, pp. 2068–2075, 2000. View at Publisher · View at Google Scholar
  6. C. R. Bankhead, C. Collins, H. Stokes-Lampard et al., “Identifying symptoms of ovarian cancer: a qualitative and quantitative study,” BJOG, vol. 115, no. 8, pp. 1008–1014, 2008. View at Publisher · View at Google Scholar
  7. R. Twombly, “Cancer killer may be “silent” no more,” Journal of the National Cancer Institute, vol. 99, no. 18, pp. 1359–1361, 2007. View at Publisher · View at Google Scholar
  8. T. H. Bourne, S. Campbell, K. M. Reynolds et al., “Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging,” British Medical Journal, vol. 306, no. 6884, pp. 1025–1029, 1993. View at Google Scholar
  9. J. R. van Nagell Jr., P. D. DePriest, M. B. Reedy et al., “The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer,” Gynecologic Oncology, vol. 77, no. 3, pp. 350–356, 2000. View at Publisher · View at Google Scholar
  10. S. Sato, Y. Yokoyama, T. Sakamoto, M. Futagami, and Y. Saito, “Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography,” Cancer, vol. 89, no. 3, pp. 582–588, 2000. View at Publisher · View at Google Scholar
  11. J. P. Lerner, I. E. Timor-Tritsch, A. Federman, and G. Abramovich, “Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system,” American Journal of Obstetrics & Gynecology, vol. 170, no. 1, pp. 81–85, 1994. View at Google Scholar
  12. D. A. Fishman, L. Cohen, S. V. Blank et al., “The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer,” American Journal of Obstetrics & Gynecology, vol. 192, no. 4, pp. 1214–1222, 2005. View at Publisher · View at Google Scholar
  13. J. R. van Nagell Jr., P. D. DePriest, F. R. Ueland et al., “Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened,” Cancer, vol. 109, no. 9, pp. 1887–1896, 2007. View at Publisher · View at Google Scholar
  14. R. J. Kurman, K. Visvanathan, R. Roden, T. C. Wu, and I.-M. Shih, “Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis,” American Journal of Obstetrics & Gynecology, vol. 198, no. 4, pp. 351–356, 2008. View at Publisher · View at Google Scholar
  15. L. Valentin, L. Skoog, and E. Epstein, “Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation,” Ultrasound in Obstetrics and Gynecology, vol. 22, no. 3, pp. 284–289, 2003. View at Publisher · View at Google Scholar
  16. E. F. C. Murta and R. S. Nomelini, “Early diagnosis and predictors of malignancy of adnexal masses,” Current Opinion in Obstetrics and Gynecology, vol. 18, no. 1, pp. 14–19, 2006. View at Publisher · View at Google Scholar
  17. U. Menon, A. Gentry-Maharaj, R. Hallett et al., “Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS),” The Lancet Oncology, vol. 10, no. 4, pp. 327–340, 2009. View at Publisher · View at Google Scholar
  18. I. J. Jacobs, S. J. Skates, N. MacDonald et al., “Screening for ovarian cancer: a pilot randomised controlled trial,” The Lancet, vol. 353, no. 9160, pp. 1207–1210, 1999. View at Publisher · View at Google Scholar
  19. I. Jacobs and R. C. Bast Jr., “The CA 125 tumour-associated antigen: a review of the literature,” Human Reproduction, vol. 4, no. 1, pp. 1–12, 1989. View at Google Scholar
  20. S. E. Kabawat, R. C. Bast Jr., A. K. Bhan, W. R. Welch, R. C. Knapp, and R. B. Colvin, “Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125,” International Journal of Gynecological Pathology, vol. 2, no. 3, pp. 275–285, 1983. View at Google Scholar
  21. R. C. Bast Jr., T. L. Klug, E. St. John et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer,” The New England Journal of Medicine, vol. 309, no. 15, pp. 883–887, 1983. View at Google Scholar
  22. P. Kenemans, G. J. van Kamp, P. Oehr, and R. A. Verstraeten, “Heterologous double determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum,” Clinical Chemistry, vol. 39, no. 12, pp. 2509–2513, 1993. View at Google Scholar
  23. K. Nustad, R. C. Bast Jr., T. J. O'Brien et al., “Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop,” Tumor Biology, vol. 17, no. 4, pp. 196–219, 1996. View at Google Scholar
  24. R. C. Bast Jr., N. Urban, V. Shridhar et al., “Early detection of ovarian cancer: promise and reality,” Cancer Treatment and Research, vol. 107, pp. 61–97, 2002. View at Google Scholar
  25. E. V. S. Høgdall, L. Christensen, S. K. Kjaer et al., “CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish “MALOVA” Ovarian Cancer Study,” Gynecologic Oncology, vol. 104, no. 3, pp. 508–515, 2007. View at Publisher · View at Google Scholar
  26. E. P. Beck, A. Moldenhauer, E. Merkle et al., “CA 125 production and release by ovarian cancer cells in vitro,” International Journal of Biological Markers, vol. 13, no. 4, pp. 200–206, 1998. View at Google Scholar
  27. C. Marth, A. G. Zeimet, G. Bock, and G. Daxenbichler, “Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells,” European Journal of Cancer Part A, vol. 28, no. 12, pp. 2002–2006, 1992. View at Google Scholar
  28. R. C. Bast Jr., M. Feeney, H. Lazarus, L. M. Nadler, R. B. Colvin, and R. C. Knapp, “Reactivity of a monoclonal antibody with human ovarian carcinoma,” Journal of Clinical Investigation, vol. 68, no. 5, pp. 1331–1337, 1981. View at Google Scholar
  29. V. R. Zurawski Jr., H. Orjaseter, A. Andersen, and E. Jellum, “Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer,” International Journal of Cancer, vol. 42, no. 5, pp. 677–680, 1988. View at Google Scholar
  30. H. Meden and A. Fattani-Meiodi, “CA 125 in benign gynecological conditions,” International Journal of Biological Markers, vol. 13, no. 4, pp. 231–237, 1998. View at Google Scholar
  31. K. J. Helzlsouer, T. L. Bush, A. J. Alberg, K. M. Bass, H. Zacur, and G. W. Comstock, “Prospective study of serum CA-125 levels as markers of ovarian cancer,” Journal of the American Medical Association, vol. 269, no. 9, pp. 1123–1126, 1993. View at Publisher · View at Google Scholar
  32. R. E. Hawkins, K. Roberts, E. Wiltshaw, J. Mundy, I. J. Fryatt, and V. R. McCready, “The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma,” British Journal of Obstetrics and Gynaecology, vol. 96, no. 12, pp. 1395–1399, 1989. View at Google Scholar
  33. A. Gadducci, P. Zola, F. Landoni et al., “Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a Multicentric Italian Study,” Gynecologic Oncology, vol. 58, no. 1, pp. 42–47, 1995. View at Publisher · View at Google Scholar
  34. S. J. Skates, U. Menon, N. MacDonald et al., “Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women,” Journal of Clinical Oncology, vol. 21, supplement 10, pp. 206s–210s, 2003. View at Google Scholar
  35. S. J. Skates, F.-J. Xu, Y.-H. Yu et al., “Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers,” Cancer, vol. 76, supplement 10, pp. 2004–2010, 1995. View at Google Scholar
  36. S. J. Skates, D. K. Pauler, and I. J. Jacobs, “Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers,” Journal of the American Statistical Association, vol. 96, pp. 429–439, 2001. View at Google Scholar
  37. R. Drapkin, H. H. von Horsten, Y. Lin et al., “Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas,” Cancer Research, vol. 65, no. 6, pp. 2162–2169, 2005. View at Publisher · View at Google Scholar
  38. R. G. Moore, A. K. Brown, M. C. Miller et al., “The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass,” Gynecologic Oncology, vol. 108, no. 2, pp. 402–408, 2008. View at Publisher · View at Google Scholar
  39. I. Hellström, J. Raycraft, M. Hayden-Ledbetter et al., “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma,” Cancer Research, vol. 63, no. 13, pp. 3695–3700, 2003. View at Google Scholar
  40. K. Huhtinen, P. Suvitie, J. Hiissa et al., “Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts,” British Journal of Cancer, vol. 100, no. 8, pp. 1315–1319, 2009. View at Publisher · View at Google Scholar
  41. R. G. Moore, D. S. McMeekin, A. K. Brown et al., “A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass,” Gynecologic Oncology, vol. 112, no. 1, pp. 40–46, 2009. View at Publisher · View at Google Scholar
  42. Z. Zhang, Y. Yu, F. Xu et al., “Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer,” Gynecologic Oncology, vol. 107, no. 3, pp. 526–531, 2007. View at Publisher · View at Google Scholar
  43. I. Visintin, Z. Feng, G. Longton et al., “Diagnostic markers for early detection of ovarian cancer,” Clinical Cancer Research, vol. 14, no. 4, pp. 1065–1072, 2008. View at Publisher · View at Google Scholar
  44. V. Nosov, F. Su, M. Amneus et al., “Validation of serum biomarkers for detection of early-stage ovarian cancer,” American Journal of Obstetrics & Gynecology, vol. 200, no. 6, pp. 639.e1–639.e5, 2009. View at Google Scholar
  45. V. W. Chen, B. Ruiz, J. L. Killeen et al., “Pathology and classification of ovarian tumors,” Cancer, vol. 97, supplement 10, pp. 2631–2642, 2003. View at Google Scholar
  46. F. A. Tavassoli and P. Devilee, Pathology and Genetics of Tumours of the Breast and Female Genital Organs, International Agency for Research on Cancer, and World Health Organization, IAPS Press, Lyon, France, 2003.
  47. L. Dubeau, “The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?” Gynecologic Oncology, vol. 72, no. 3, pp. 437–442, 1999. View at Publisher · View at Google Scholar
  48. N. Auersperg, T. Ota, and G. W. E. Mitchell, “Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches,” International Journal of Gynecological Cancer, vol. 12, no. 6, pp. 691–703, 2002. View at Publisher · View at Google Scholar
  49. J. D. Seidman, I. Horkayne-Szakaly, M. Haiba, C. R. Boice, R. J. Kurman, and B. M. Ronnett, “The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin,” International Journal of Gynecological Pathology, vol. 23, no. 1, pp. 41–44, 2004. View at Publisher · View at Google Scholar
  50. C. N. Landen Jr., M. J. Birrer, and A. K. Sood, “Early events in the pathogenesis of epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 995–1005, 2008. View at Publisher · View at Google Scholar
  51. I.-M. Shih and R. J. Kurman, “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis,” American Journal of Pathology, vol. 164, no. 5, pp. 1511–1518, 2004. View at Google Scholar
  52. D. S. McMeekin, R. A. Burger, A. Manetta, P. DiSaia, and M. L. Berman, “Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis,” Gynecologic Oncology, vol. 59, no. 1, pp. 81–86, 1995. View at Publisher · View at Google Scholar
  53. H. Yoshikawa, H. Jimbo, S. Okada et al., “Prevalence of endometriosis in ovarian cancer,” Gynecologic and Obstetric Investigation, vol. 50, supplement 1, pp. 11–17, 2000. View at Google Scholar
  54. M. Erzen, S. Rakar, B. Klancnik, and K. Syrjanen, “Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study,” Gynecologic Oncology, vol. 83, no. 1, pp. 100–108, 2001. View at Publisher · View at Google Scholar
  55. S. C. Modesitt, G. Tortolero-Luna, J. B. Robinson, D. M. Gershenson, and J. K. Wolf, “Ovarian and extraovarian endometriosis-associated cancer,” Obstetrics and Gynecology, vol. 100, no. 4, pp. 788–795, 2002. View at Publisher · View at Google Scholar
  56. R. C. Stern, R. Dash, R. C. Bentley, M. J. Snyder, A. F. Haney, and S. J. Robboy, “Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types,” International Journal of Gynecological Pathology, vol. 20, no. 2, pp. 133–139, 2001. View at Google Scholar
  57. R. Sainz de la Cuesta, J. H. Eichhorn, L. W. Rice, A. F. Fuller Jr., N. Nikrui, and B. A. Goff, “Histologic transformation of benign endometriosis to early epithelial ovarian cancer,” Gynecologic Oncology, vol. 60, no. 2, pp. 238–244, 1996. View at Publisher · View at Google Scholar
  58. E. J. Thomas and I. G. Campbell, “Molecular genetic defects in endometriosis,” Gynecologic and Obstetric Investigation, vol. 50, supplement 1, pp. 44–50, 2000. View at Google Scholar
  59. H. Itamochi, J. Kigawa, T. Sugiyama, Y. Kikuchi, M. Suzuki, and N. Terakawa, “Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary,” Obstetrics and Gynecology, vol. 100, no. 2, pp. 281–287, 2002. View at Publisher · View at Google Scholar
  60. T. Sugiyama, T. Kamura, J. Kigawa et al., “Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy,” Cancer, vol. 88, no. 11, pp. 2584–2589, 2000. View at Publisher · View at Google Scholar
  61. D. R. Schwartz, S. L. R. Kardia, K. A. Shedden et al., “Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas,” Cancer Research, vol. 62, no. 16, pp. 4722–4729, 2002. View at Google Scholar
  62. S. Marchini, P. Mariani, G. Chiorino et al., “Analysis of gene expression in early-stage ovarian cancer,” Clinical Cancer Research, vol. 14, no. 23, pp. 7850–7860, 2008. View at Publisher · View at Google Scholar
  63. M. V. Iorio, R. Visone, G. Di Leva et al., “MicroRNA signatures in human ovarian cancer,” Cancer Research, vol. 67, no. 18, pp. 8699–8707, 2007. View at Publisher · View at Google Scholar
  64. K. K. Zorn, T. Bonome, L. Gangi et al., “Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer,” Clinical Cancer Research, vol. 11, no. 18, pp. 6422–6430, 2005. View at Publisher · View at Google Scholar
  65. T. Bonome, J.-Y. Lee, D.-C. Park et al., “Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary,” Cancer Research, vol. 65, no. 22, pp. 10602–10612, 2005. View at Publisher · View at Google Scholar
  66. M. Kobel, S. E. Kalloger, N. Boyd et al., “Ovarian carcinoma subtypes are different diseases: implications for biomarker studies,” PLoS Medicine, vol. 5, no. 12, article e232, 2008. View at Google Scholar
  67. G. Singer, R. Stöhr, L. Cope et al., “Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation,” The American Journal of Surgical Pathology, vol. 29, no. 2, pp. 218–224, 2005. View at Publisher · View at Google Scholar
  68. S. A. Cannistra, “Cancer of the ovary,” The New England Journal of Medicine, vol. 351, no. 24, pp. 2519–2529, 2004. View at Publisher · View at Google Scholar
  69. S. A. South, H. Vance, C. Farrell et al., “Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers,” Cancer, vol. 115, no. 2, pp. 324–333, 2009. View at Publisher · View at Google Scholar
  70. R. Scully and D. M. Livingston, “In search of the tumour-suppressor functions of BRCA1 and BRCA2,” Nature, vol. 408, no. 6811, pp. 429–432, 2000. View at Publisher · View at Google Scholar
  71. M. Tsai-Turton, A. Santillan, D. Lu et al., “p53 autoantibodies, cytokine levels and ovarian carcinogenesis,” Gynecologic Oncology, vol. 114, no. 1, pp. 12–17, 2009. View at Google Scholar
  72. T. J. Herzog and B. Pothuri, “Ovarian cancer: a focus on management of recurrent disease,” Nature Clinical Practice Oncology, vol. 3, no. 11, pp. 604–611, 2006. View at Publisher · View at Google Scholar
  73. N. Auersperg, S. L. Maines-Bandiera, H. G. Dyck, and P. A. Kruk, “Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes,” Laboratory Investigation, vol. 71, no. 4, pp. 510–518, 1994. View at Google Scholar
  74. B. Czernobilsky, R. Moll, R. Levy, and W. W. Franke, “Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary,” European Journal of Cell Biology, vol. 37, pp. 175–190, 1985. View at Google Scholar
  75. C. H. Siemens and N. Auersperg, “Serial propagation of human ovarian surface epithelium in tissue culture,” Journal of Cellular Physiology, vol. 134, no. 3, pp. 347–356, 1988. View at Google Scholar
  76. P. A. Kruk, V.-J. Uitto, J. D. Firth, S. Dedhar, and N. Auersperg, “Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix,” Experimental Cell Research, vol. 215, no. 1, pp. 97–108, 1994. View at Publisher · View at Google Scholar
  77. W. J. Murdoch and J. F. Martinchick, “Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention,” Experimental Biology and Medicine, vol. 229, no. 6, pp. 546–552, 2004. View at Google Scholar
  78. R. Drapkin and J. L. Hecht, “Pathogenesis of ovarian cancer,” in Diagnostic gynecologic and obstetric pathology, Elsevier Saunders, Philadelphia, Pa, USA, 2006. View at Google Scholar
  79. R. Drapkin, C. P. Crum, and J. L. Hecht, “Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia,” Human Pathology, vol. 35, no. 8, pp. 1014–1021, 2004. View at Publisher · View at Google Scholar
  80. L. Dubeau, “The cell of origin of ovarian epithelial tumours,” The Lancet Oncology, vol. 9, no. 12, pp. 1191–1197, 2008. View at Publisher · View at Google Scholar
  81. A. S. T. Wong and P. C. K. Leung, “Role of endocrine and growth factors on the ovarian surface epithelium,” Journal of Obstetrics and Gynaecology Research, vol. 33, no. 1, pp. 3–16, 2007. View at Publisher · View at Google Scholar
  82. J. Permuth-Wey and T. A. Sellers, “Epidemiology of ovarian cancer,” Methods in Molecular Biology, vol. 472, pp. 413–437, 2009. View at Google Scholar
  83. B. H. Ortiz, M. Ailawadi, C. Colitti et al., “Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors,” Cancer Research, vol. 61, no. 19, pp. 7264–7267, 2001. View at Google Scholar
  84. R. F. Caduff, S. M. Svoboda-Newman, A. W. Ferguson, C. M. Johnston, and T. S. Frank, “Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors,” The American Journal of Surgical Pathology, vol. 23, no. 3, pp. 323–328, 1999. View at Publisher · View at Google Scholar
  85. G. Singer, R. J. Kurman, H.-W. Chang, S. K. R. Cho, and I.-M. Shih, “Diverse tumorigenic pathways in ovarian serous carcinoma,” American Journal of Pathology, vol. 160, no. 4, pp. 1223–1228, 2002. View at Google Scholar
  86. J. D. Seidman and R. J. Kurman, “Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases,” The American Journal of Surgical Pathology, vol. 20, no. 11, pp. 1331–1345, 1996. View at Publisher · View at Google Scholar
  87. A. E. S. Sehdev, P. S. Sehdev, and R. J. Kurman, “Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases,” The American Journal of Surgical Pathology, vol. 27, no. 6, pp. 725–736, 2003. View at Publisher · View at Google Scholar
  88. C. Peyssonnaux and A. Eychene, “The Raf/MEK/ERK pathway: new concepts of activation,” Biology of the Cell, vol. 93, no. 1-2, pp. 53–62, 2001. View at Publisher · View at Google Scholar
  89. G. Singer, R. Oldt III, Y. Cohen et al., “Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 6, pp. 484–486, 2003. View at Google Scholar
  90. K. Obata, S. J. Morland, R. H. Watson et al., “Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors,” Cancer Research, vol. 58, no. 10, pp. 2095–2097, 1998. View at Google Scholar
  91. D. Shahbazian, P. P. Roux, V. Mieulet et al., “The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity,” The EMBO Journal, vol. 25, no. 12, pp. 2781–2791, 2006. View at Publisher · View at Google Scholar
  92. E. Janda, K. Lehmann, I. Killisch et al., “Ras and TGFß cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways,” Journal of Cell Biology, vol. 156, no. 2, pp. 299–313, 2002. View at Publisher · View at Google Scholar
  93. M. Sabbah, S. Emami, G. Redeuilh et al., “Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers,” Drug Resistance Updates, vol. 11, no. 4-5, pp. 123–151, 2008. View at Publisher · View at Google Scholar
  94. W.-Y. Chan, K.-K. Cheung, J. O. Schorge et al., “Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers,” American Journal of Pathology, vol. 156, no. 2, pp. 409–417, 2000. View at Google Scholar
  95. M. F. Kohler, J. R. Marks, R. W. Wiseman et al., “Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer,” Journal of the National Cancer Institute, vol. 85, no. 18, pp. 1513–1519, 1993. View at Google Scholar
  96. J. Kupryjanczyk, A. D. Thor, R. Beauchamp et al., “p53 gene mutations and protein accumulation in human ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 11, pp. 4961–4965, 1993. View at Google Scholar
  97. W.-H. Wen, A. Reles, I. B. Runnebaum et al., “p53 mutations and expression in ovarian cancers: correlation with overall survival,” International Journal of Gynecological Pathology, vol. 18, no. 1, pp. 29–41, 1999. View at Google Scholar
  98. J. S. Ross, F. Yang, B. V. S. Kallakury, C. E. Sheehan, R. A. Ambros, and P. J. Muraca, “HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary,” American Journal of Clinical Pathology, vol. 111, no. 3, pp. 311–316, 1999. View at Google Scholar
  99. J. Q. Cheng, A. K. Godwin, A. Bellacosa et al., “AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 19, pp. 9267–9271, 1992. View at Publisher · View at Google Scholar
  100. H. A. Risch, J. R. McLaughlin, D. E. C. Cole et al., “Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada,” Journal of the National Cancer Institute, vol. 98, no. 23, pp. 1694–1706, 2006. View at Publisher · View at Google Scholar
  101. R. Wooster and B. L. Weber, “Breast and ovarian cancer,” The New England Journal of Medicine, vol. 348, no. 23, pp. 2339–2347, 2003. View at Publisher · View at Google Scholar
  102. J. M. J. Piek, P. J. van Diest, R. P. Zweemer et al., “Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer,” Journal of Pathology, vol. 195, no. 4, pp. 451–456, 2001. View at Publisher · View at Google Scholar
  103. M. L. Carcangiu, P. Radice, S. Manoukian et al., “Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carrier,” International Journal of Gynecological Pathology, vol. 23, no. 1, pp. 35–40, 2004. View at Publisher · View at Google Scholar
  104. A. Finch, P. Shaw, B. Rosen, J. Murphy, S. A. Narod, and T. J. Colgan, “Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers,” Gynecologic Oncology, vol. 100, no. 1, pp. 58–64, 2006. View at Publisher · View at Google Scholar
  105. K. Leeper, R. Garcia, E. Swisher, B. Goff, B. Greer, and P. Paley, “Pathologic findings in prophylactic oophorectomy specimens in high-risk women,” Gynecologic Oncology, vol. 87, no. 1, pp. 52–56, 2002. View at Publisher · View at Google Scholar
  106. F. Medeiros, M. G. Muto, Y. Lee et al., “The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome,” The American Journal of Surgical Pathology, vol. 30, no. 2, pp. 230–236, 2006. View at Publisher · View at Google Scholar
  107. D. W. Kindelberger, Y. Lee, A. Miron et al., “Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship,” The American Journal of Surgical Pathology, vol. 31, no. 2, pp. 161–169, 2007. View at Publisher · View at Google Scholar
  108. Y. Lee, A. Miron, R. Drapkin et al., “A candidate precursor to serous carcinoma that originates in the distal fallopian tube,” Journal of Pathology, vol. 211, no. 1, pp. 26–35, 2007. View at Publisher · View at Google Scholar
  109. E. P. Rogakou, C. Boon, C. Redon, and W. M. Bonner, “Megabase chromatin domains involved in DNA double-strand breaks in vivo,” Journal of Cell Biology, vol. 146, no. 5, pp. 905–915, 1999. View at Publisher · View at Google Scholar
  110. A. K. Folkins, E. A. Jarboe, A. Saleemuddin et al., “A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations,” Gynecologic Oncology, vol. 109, no. 2, pp. 168–173, 2008. View at Publisher · View at Google Scholar
  111. K. Levanon, C. Crum, and R. Drapkin, “New insights into the pathogenesis of serous ovarian cancer and its clinical impact,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5284–5293, 2008. View at Publisher · View at Google Scholar
  112. A. Saleemuddin, A. K. Folkins, L. Garrett et al., “Risk factors for a serous cancer precursor (“p53 signature”) in women with inherited BRCA mutations,” Gynecologic Oncology, vol. 111, no. 2, pp. 226–232, 2008. View at Publisher · View at Google Scholar
  113. A. K. Folkins, E. A. Jarboe, M. H. Roh, and C. P. Crum, “Precursors to pelvic serous carcinoma and their clinical implications,” Gynecologic Oncology, vol. 113, no. 3, pp. 391–396, 2009. View at Publisher · View at Google Scholar
  114. D. C. Connolly, R. Bao, A. Y. Nikitin et al., “Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer,” Cancer Research, vol. 63, no. 6, pp. 1389–1397, 2003. View at Google Scholar
  115. A. Flesken-Nikitin, K.-C. Choi, J. P. Eng, E. N. Shmidt, and A. Y. Nikitin, “Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium,” Cancer Research, vol. 63, no. 13, pp. 3459–3463, 2003. View at Google Scholar
  116. S. Orsulic, Y. Li, R. A. Soslow, L. A. Vitale-Cross, J. S. Gutkind, and H. E. Varmus, “Induction of ovarian cancer by defined multiple genetic changes in a mouse model system,” Cancer Cell, vol. 1, no. 1, pp. 53–62, 2002. View at Publisher · View at Google Scholar
  117. D. M. Dinulescu, T. A. Ince, B. J. Quade, S. A. Shafer, D. Crowley, and T. Jacks, “Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer,” Nature Medicine, vol. 11, no. 1, pp. 63–70, 2005. View at Publisher · View at Google Scholar
  118. R. Wu, N. Hendrix-Lucas, R. Kuick et al., “Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/ß-catenin and PI3K/Pten signaling pathways,” Cancer Cell, vol. 11, no. 4, pp. 321–333, 2007. View at Publisher · View at Google Scholar
  119. T. Umezu, M. Hanazono, S. Aizawa, and Y. Tomooka, “Characterization of newly established clonal oviductal cell lines and differential hormonal regulation of gene expression,” In Vitro Cellular and Developmental Biology—Animal, vol. 39, no. 3-4, pp. 146–156, 2003. View at Google Scholar
  120. Y.-L. Lee, K.-F. Lee, J.-S. Xu, Y.-L. Wang, S.-W. Tsao, and W. S. B. Yeung, “Establishment and characterization of an immortalized human oviductal cell line,” Molecular Reproduction and Development, vol. 59, no. 4, pp. 400–409, 2001. View at Publisher · View at Google Scholar
  121. M. T. Comer, H. J. Leese, and J. Southgate, “Induction of a differentiated ciliated cell phenotype in primary cultures of Fallopian tube epithelium,” Human Reproduction, vol. 13, no. 11, pp. 3114–3120, 1998. View at Google Scholar
  122. H. Ando, M. Kobayashi, S. Toda, F. Kikkawa, T. Masahashi, and S. Mizutani, “Establishment of a ciliated epithelial cell line from human Fallopian tube,” Human Reproduction, vol. 15, no. 7, pp. 1597–1603, 2000. View at Google Scholar
  123. T. Henriksen, T. Tanbo, T. Abyholm, B. R. Oppedal, O. P. Claussen, and T. Hovig, “Epithelial cells from human Fallopian tube in culture,” Human Reproduction, vol. 5, no. 1, pp. 25–31, 1990. View at Google Scholar
  124. A. Bongso, S. C. Ng, H. Sathananthan, P. L. Ng, M. Rauff, and S. S. Ratnam, “Establishment of human ampullary cell cultures,” Human Reproduction, vol. 4, no. 5, pp. 486–494, 1989. View at Google Scholar
  125. M. Rajagopal, T. L. Tollner, W. E. Finkbeiner, G. N. Cherr, and J. H. Widdicombe, “Differentiated structure and function of primary cultures of monkey oviductal epithelium,” In Vitro Cellular and Developmental Biology—Animal, vol. 42, no. 8-9, pp. 248–254, 2006. View at Google Scholar
  126. P. D. Vermeer, L. A. Einwalter, T. O. Moninger et al., “Segregation of receptor and ligand regulates activation of epithelial growth factor receptor,” Nature, vol. 422, no. 6929, pp. 322–326, 2003. View at Publisher · View at Google Scholar
  127. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” The New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar
  128. J. A. Joyce and J. W. Pollard, “Microenvironmental regulation of metastasis,” Nature Reviews Cancer, vol. 9, no. 4, pp. 239–252, 2009. View at Publisher · View at Google Scholar